Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer.

Medicine - 23 Feb 2024

Chen Jianxin, Zheng Qinhong, Wang Junhui, Zhang Xueli, Lv Yingguo

Abstract excerpt

The present study was conducted to characterize the clinicopathologic characteristics, immunohistochemical staining results, and immune checkpoint inhibitors (ICIs) efficacy in patients with SMARCA4-deficient/TP53 mutant lung cancer. Patients diagnosed with advanced or metastatic undifferentiated lung cancer harboring SMARCA4-deficient and TP53 mutations, however, without targetable sensitive mutations were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to DNA Helicases

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Nuclear Proteins

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 38394494
DOI: 10.1097/MD.0000000000036959
PMCID: PMC11309689

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer.PMID 38394494Read ↗

Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.Semantic proximity Read ↗

Effective treatment strategies and key factors influencing therapeutic efficacy in advanced SMARCA4-deficient non-small cell lung cancer.Semantic proximity Read ↗

Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53.Semantic proximity Read ↗

Clinicopathological characteristics and treatment outcomes of advanced SMARCA4-deficient thoracic tumors.Semantic proximity Read ↗

Heterogeneity in advanced pulmonary sarcomatoid carcinoma and its efficacy to immune checkpoint inhibitors.Semantic proximity Read ↗

Clinical characteristics and association with immunotherapy outcomes in SMARCA4-deficient NSCLCSemantic proximity Read ↗

Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma.Semantic proximity Read ↗

Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.Semantic proximity Read ↗

[Clinical characteristics and prognostic analysis of thoracic SMARCA4-deficient undifferentiated tumor].Semantic proximity Read ↗

Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients.Semantic proximity Read ↗

USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer.Semantic proximity Read ↗

A Critical Review of the Impact of SMARCA4 Mutations on Survival Outcomes in Non-Small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.